Takaki Yoshikawa

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh et al. · The Lancet · 2017 · 2.2K citations · Full text

Esophageal Cancer, Gastrointestinal Oncology, Least Two +8

Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer

Jakob Nikolas Kather, Alexander T. Pearson, Niels Halama et al. · Nature Medicine · 2019 · 1.3K citations · Full text

Engineering, Deep Learning, Medicine +10

Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial

Kazumasa Fujitani, Han‐Kwang Yang, Junki Mizusawa et al. · The Lancet Oncology · 2016 · 688 citations

Single Non-curable Factor, Surgical Oncology, Gastrointestinal Oncology +8

Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer: Japan Clinical Oncology Group Study JCOG0912

Hitoshi Katai, Junki Mizusawa, Hiroshi Katayama et al. · Gastric Cancer · 2016 · 382 citations · Full text

Laparoscopy, Surgical Oncology, Short-term Surgical Outcomes +7

Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial

Kazuhiro Yoshida, Yasuhiro Kodera, Mitsugu Kochi et al. · Journal of Clinical Oncology · 2019 · 381 citations · Full text